2H10 milestones

2H10 milestones

Selected products with Phase III or regulatory milestones expected in 2H10
Company Product Indication Event Milestone
Actelion Ltd. (SIX:ATLN) Pivlaz clazosentan Prevent the occurrence of cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH) Ph III data October
Adventrx Pharmaceuticals Inc.(NYSE-A:ANX) Exelbine vinorelbine emulsion (ANX-530) Non-small cell lung cancer (NSCLC) Submit NDA 4Q10
Alexza Pharmaceuticals Inc. (NASDAQ:ALXA)/Biovail Corp. (TSX:BVF; NYSE:BVF) Staccato loxapine (AZ-004) Agitation in patients with schizophrenia or bipolar disorder PDUFA date 10/11/10
Alkermes Inc. (NASDAQ:ALKS) Vivitrol naltrexone Opioid dependence FDA panel meeting; PDUFA date 9/16/10; 10/12/10
Allos Therapeutics Inc. (NASDAQ:ALTH) Folotyn pralatrexate Peripheral T cell lymphoma (PTCL) Submit MAA 4Q10
Almirall S.A. (Madrid:ALM)/Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD)/ Forest Laboratories Inc. (NYSE:FRX)/Astellas Pharma Inc. (Tokyo:4503) Linaclotide Irritable bowel syndrome with constipation (IBS-C) Ph III data 4Q10
Amgen Inc. (NASDAQ:AMGN) Prolia denosumab Prevent or delay bone metastases in prostate cancer patients Ph III data 4Q10
Amylin Pharmaceuticals Inc. (NASDAQ:AMLN)/ Eli Lilly and Co. (NYSE:LLY) Bydureon exenatide once weekly; uses drug delivery technology from Alkermes Inc. (NASDAQ:ALKS) Type II diabetes PDUFA date 10/22/10
Anika Therapeutics Inc. (NASDAQ:ANIK) Monovisc Pain caused by osteoarthritis (OA)

Read the full 2300 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers